Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia

Bibliographic Information
Authors: Elyamany G.; Alzahrani A.M.; Aljuboury M.; mogadem N.; Rehan N.; Alsuhaibani O.; Alabdulaaly A.; Al-Mussaed E.; Elhag I.; AlFiaar A.
Journal: Diagnostic Pathology
Publisher: BioMed Central Ltd.
Publication Date: 25 June 2015
Volume / Issue: Volume 10 / Issue 1
Article No.: 78
ISSN: 17461596
DOI: 10.1186/s13000-015-0315-z
Scopus: View on Scopus
PubMed: 26108914
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Elyamany G., Department of Pathology and Laboratory Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, Department of Hematology and Blood Bank, Theodor Bilharz Research Institute, Giza, Egypt; Alzahrani A.M., Department of Hematology and Blood Bank, Theodor Bilharz Research Institute, Giza, Egypt, Department of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Aljuboury M., Department of Pathology and Laboratory Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; mogadem N., Department of Pathology and Laboratory Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Rehan N., Department of Hematology and Blood Bank, Theodor Bilharz Research Institute, Giza, Egypt; Alsuhaibani O., Department of Pathology and Laboratory Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Alabdulaaly A., Department of Pathology and Laboratory Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Al-Mussaed E., Department of Basic Science, Princess Nourah Bint Abdulrahman University, College of Medicine, Riyadh, Saudi Arabia; Elhag I., Department of Pathology and Laboratory Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; AlFiaar A., Department of Pathology and Laboratory Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Abstract
Background: Plasmablastic lymphoma (PBL) is a rare subtype of non-Hodgkin's lymphoma. Characterized by its aggressive nature and plasmacytic differentiation, PBL remains a therapeutic and diagnostic challenge; it generally has a poor prognosis with very few long-term survivors and most patients dying within 2 years from initial presentation. PBL has been reported in several other countries; however, there have been no reportedcases from Saudi Arabia. Here, we report 8 cases of PBL depicting the clinical presentation, immunocompetency, immunphenotypic characterization, diagnostic challenges and treatment outcome. Methods: The medical records were reviewed for clinical presentation, staging, laboratory data, radiological studies, treatments, and outcomes. A broad immunohistochemical panel consisting of CD45, CD3, CD20, CD79a, Pax5, CD38, CD138, MUM1, EMA, Kappa, Lambda, CD 56, CD30, Bcl-2, Bcl-6, Alk-1, Ki-67, EBV-LMP-1, and HHV8 was performed. Results: The tumors predominantly exhibited immunoblastic/plasmablastic or plasmacytic morphologic features and had a plasma cell-like immunophenotype. All cases were immunoreactive for CD38, CD138 and MUM1 confirming plasma cell differentiation of the tumor cells. CD20 was negative for all cases; whereas CD79a and Pax5 were weakly positive in 2cases. All 8 cases were EBV-LMP-1/EBER-1 negative, and 1 case was HHV8 positive. Similar to previously published studies, PBL in Saudi Arabia is characterized by male predominance (6/8), median age 51.5 years (mean age 46 years), associated with early dissemination, poor response to therapy, and limited survival (average survival time, 6.4 months, median overall survival 5.5 months). However, it does have some unique features. It occurs more commonly in immunocompetent persons (6/8, 75 %), is not associated with EBV infection (0/8), and nodal involvement (either primary or secondary) is common among patients (6/8). In addition, extra-oral sites are more common than oral/nasal cavities (7/8) and the c-myc gene is not common (1/8, 12.5 %). Conclusion: It appears that PBL is heterogeneous in terms of clinical presentation and morphology. PBL is a therapeutic challenge with a clinical course that is characterized by its high rate of relapse and death. To date, treatment responses are usually partial and temporary. Therapies that are more intensive than CHOP do not seem to prolong survival. Further research is needed to understand the biology and molecular pathogenesis of PBL in order to improve therapies. Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1465801416161912 © 2015 Elyamany et al.
Keywords
Chemotherapy; HIV; Outcome; Plasmablastic lymphoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Female; Herpesvirus 8, Human; Humans; Immunocompetence; Immunohistochemistry; Immunophenotyping; In Situ Hybridization, Fluorescence; Male; Middle Aged; Predictive Value of Tests; Proto-Oncogene Proteins c-myc; Risk Factors; Saudi Arabia; Survival Analysis; Time Factors; Treatment Outcome; Young Adult; antineoplastic agent; Myc protein; MYC protein, human; tumor marker; chemistry; fluorescence in situ hybridization; genetics; human; Human herpesvirus 8; immunology; isolation and purification; mortality; pathology; predictive value; risk factor; time factor; virology
Citation Information
Scopus Citations: 20
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
